Trial Profile
Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 01 Feb 2010 Results published in JCO.
- 03 May 2007 New trial record.